Navigation Links
IRIDEX Expands ENT Laser Applications
Date:8/31/2011

MOUNTAIN VIEW, Calif., Aug. 31, 2011 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced the introduction of its new XP Module - a high power factory installed option for the IRIDEX IQ 532 green laser system. The IQ 532 XP is a multifunctional device that can be utilized by both ear, nose and throat (ENT) surgeons and ophthalmologists - expanding overall utilization and making a laser investment more attractive.

The optional XP module doubles the power of the standard IRIDEX IQ 532, facilitating the rapid and efficient treatment of tissue while limiting unwanted thermal effects and provides ENT surgeons with a portable KTP 532 nm laser system that is optimized for their clinical needs.

"We developed the XP module in response to the growing demand from ENT surgeons for higher power output, particularly for use when treating laryngeal pathologies," commented Theodore A. Boutacoff, President & CEO. "When used with our family of ENT probes, physicians are now able to expand their treatment capabilities and achieve clinically effective results in less time. The IQ 532 with the XP Module and the IRIDEX family of ENT probes are optimized for the treatment of soft tissue/vascular lesions of the airway and larynx, including polyps and adhesions."

The addition of the XP Module and FlexFiber delivery devices to our existing ENT product line provides additional sales opportunities and demonstrates IRIDEX's dedication to providing physicians with innovative tools to enhance surgical procedures while improving patient and clinical outcomes.

About IQ 532 with XP Module

Our IQ 532 products are small, portable, depot serviced, and efficient solid state semiconductor-based laser systems. Some notable features include a modern touch screen user interface, wireless foot switch control, and voice confirmation. System setup is quick and easy. With the incorporation of the XP module, the IQ 532 offers significantly higher laser power capabilities for ENT, while retaining all of the user interface features and device compatibility of our standard IQ 532 product.

About ENT Delivery Devices

FlexFiber laser probes are a family of single-use, laser delivery devices available in a range of fiber diameters. Compatible with all common flexible scopes, they are used for laser delivery during laryngeal surgeries and are intended for the treatment of soft tissue/vascular lesions of the airway and larynx, including polyps and adhesions. IRIDEX's family of OtoProbe™ delivery devices are used for laser delivery during otologic surgeries and are indicated for, but not limited to, incision, excision, coagulation, and vaporization of soft and fibrous tissue, including osseous tissue.

About IRIDEX Corporation

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's sales opportunities, growth initiatives and new products.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 1, 2011 and our Quarterly Reports on Form 10-Q for the quarters ended April 2, 2011 and July 2, 2011, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting
2. IRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology
3. IRIDEX Introduces IQ 532 Dual Port Green Laser System at the American Academy of Ophthalmology
4. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
5. IRIDEX Announces Fourth Quarter and Full Year 2009 Conference Call and Release Date
6. IRIDEX Reports Fourth Quarter and Full Year 2009 Financial Results
7. IRIDEX Announces First Quarter 2010 Conference Call and Release Date
8. IRIDEX Announces First Commercial Shipment of New IQ 532(TM) Laser Systems
9. IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery
10. IRIDEX Announces Second Quarter 2010 Conference Call and Release Date
11. IRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe® Device for Eye Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center for ... Table in Battle Creek, MI, where the rehabilitation facility is located. This annual celebration ... world’s leading providers of cereal and other breakfast foods. Its residents often refer to ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):